<p>Assenagon Asset Management S.A. 在最近向美国证券交易委员会提交的文件中表示，在第三季度将其在 Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - 免费报告) 的持股比例减少了 91.9%。该基金在季度内出售了 220,675 股后，持有该生物技术公司 19,330 股股票。Assenagon Asset Management S.A. 在最近一个季度末持有 Rigel Pharmaceuticals 0.11% 的股份，价值 548,000 美元。</p>
<p>其他几家机构投资者最近也增持或减持了该股票的持股。Armistice Capital LLC 在第二季度将其在 Rigel Pharmaceuticals 的持股比例增加了 5.5%。Armistice Capital LLC 目前持有该生物技术公司 1,600,000 股股票，价值 29,968,000 美元，此前在该期间内又增购了 84,000 股。Dynamic Technology Lab Private Ltd 在第一季度购买了 Rigel Pharmaceuticals 的新股份，价值约 488,000 美元。Strs Ohio 在第一季度购买了 Rigel Pharmaceuticals 的新股份，价值约 389,000 美元。Acadian Asset Management LLC 在第一季度将其在 Rigel Pharmaceuticals 的持股比例提高了 50.1%。Acadian Asset Management LLC 目前持有该生物技术公司 565,045 股股票，价值 10,161,000 美元，此前在上个季度又购买了 188,679 股。最后，Jacobs Levy Equity Management Inc. 在第一季度将其在 Rigel Pharmaceuticals 的持股比例增加了 7.8%。Jacobs Levy Equity Management Inc. 目前持有该生物技术公司 217,776 股股票，价值 3,918,000 美元，此前在该期间内又购买了 15,687 股。机构投资者持有该公司 66.23% 的股份。</p>
<p>获取 <strong>Rigel Pharmaceuticals</strong> 的提醒：</p>
<h2>Rigel Pharmaceuticals 价格表现</h2>
<p>NASDAQ:RIGL 的股票周五开盘价为 44.66 美元。该公司的 50 日移动平均线为 39.93 美元，200 日移动平均线为 32.11 美元。该公司的流动比率为 2.28，速动比率为 2.14，债务与股本比率为 0.25。该股票的市值为 8.1058 亿美元，市盈率为 7.24，贝塔值为 1.11。Rigel Pharmaceuticals, Inc. 的 12 个月低点为 15.50 美元，12 个月高点为 52.24 美元。</p>
<p>Rigel Pharmaceuticals (NASDAQ:RIGL - 获取免费报告) 最近于 11 月 4 日（星期二）公布了季度财报。这家生物技术公司报告季度每股收益为 1.46 美元，超出市场共识预期的 0.93 美元，超出幅度为 0.53 美元。该公司在季度内的收入为 6946 万美元，而市场共识预期为 6188 万美元。Rigel Pharmaceuticals 的净利润率为 40.17%，股本回报率为 204.70%。整体来看，卖方分析师预测 Rigel Pharmaceuticals, Inc. 本财年将发布 0.22 美元的每股收益。</p>
<h2>分析师设定新目标价</h2>
<p>几位分析师对该公司发布了报告。Weiss Ratings 在 10 月 8 日（星期三）的研究报告中重申了对 Rigel Pharmaceuticals 股票的 &#34;持有 (c+)&#34; 评级。华尔街 Zen 在 12 月 21 日（星期日）的报告中将 Rigel Pharmaceuticals 的评级从 &#34;持有&#34; 上调至 &#34;买入&#34;。Zacks Research 在 12 月 5 日（星期五）的研究报告中将 Rigel Pharmaceuticals 的评级从 &#34;强力买入&#34; 下调至 &#34;持有&#34;。Jefferies Financial Group 在 11 月 5 日（星期三）的研究报告中将 Rigel Pharmaceuticals 的评级从 &#34;持有&#34; 上调至 &#34;买入&#34;，并将该股票的目标价从 23.00 美元提高至 42.00 美元。最后，Cantor Fitzgerald 在 11 月 5 日（星期三）的研究报告中将 Rigel Pharmaceuticals 的目标价从 32.00 美元提高至 38.00 美元，并给予该股票 &#34;中性&#34; 评级。三位研究分析师对该股票给予了买入评级，四位分析师对该公司的股票给予了持有评级。根据 MarketBeat 的数据，该公司的共识评级为 &#34;持有&#34;，平均目标价为 43.20 美元。</p>
<p><strong>查看我们对 Rigel Pharmaceuticals 的最新股票分析</strong></p>
<h2>Rigel Pharmaceuticals 公司简介</h2>
<p>(免费报告)</p>
<p>Rigel Pharmaceuticals, Inc. 是一家临床阶段的生物制药公司，总部位于加利福尼亚州南旧金山。公司成立于 2003 年，专注于发现、开发和商业化针对免疫、血液和肿瘤疾病的新型小分子治疗药物。利用专有的化学平台和信号转导通路的专业知识，该公司旨在解决稀有和常见疾病中显著未满足的医疗需求。</p>
<p>Rigel 的主要产品 fostamatinib（商业名称为 Tavalisse®）是一种口服脾酪氨酸激酶 (SYK) 抑制剂，已在美国获得批准，用于治疗慢性免疫性血小板减少症 (ITP) 的成年患者。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票，而不是 Rigel Pharmaceuticals</li>
<li>在 1 月 1 日之前将 1,000 美元投入这只股票 [不是 NVDA]</li>
<li>将你的 &#34;死钱&#34; 转变为每月 306 美元以上（从这个月开始）</li>
<li>华盛顿为战争做准备</li>
<li>奇怪的晶体金属性能超过硅达 100 倍</li>
<li>来自奇怪的新 “AI 燃料” 的 33,000% 繁荣？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUX9TeW1ib2w9UklHTA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUX9TeW1ib2w9UklHTA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Rigel Pharmaceuticals 吗？</h2>
<p>在你考虑 Rigel Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄地向客户推荐的股票，以便在更广泛的市场注意到之前购买... 而 Rigel Pharmaceuticals 并不在名单上。</p>
<p>虽然 Rigel Pharmaceuticals 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看五只股票</p>

Rigel制药

<p>Assenagon Asset Management S.A. 在第三季度将其在 Rigel Pharmaceuticals 的持股减少了 91.9%，目前持有 19,330 股，价值 548,000 美元。其他投资者也调整了他们的持仓，Armistice Capital LLC 增加了 5.5% 的持股。Rigel 的股票开盘价为 44.66 美元，市值为 8.1058 亿美元。分析师的评级各异，普遍意见为 “持有”，平均目标价为 43.20 美元</p>

<p>Assenagon Asset Management S.A. reduced its stake in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) by 91.9% during the third quarter, according to its most recent filing with the SEC. The fund owned 19,330 shares of the biotechnology company's stock after selling 220,675 shares during the quarter. Assenagon Asset Management S.A. owned 0.11% of Rigel Pharmaceuticals worth $548,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Assenagon Asset Management S.A. 在最近向美国证券交易委员会提交的文件中表示，在第三季度将其在 Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - 免费报告) 的持股比例减少了 91.9%。该基金在季度内出售了 220,675 股后，持有该生物技术公司 19,330 股股票。Assenagon Asset Management S.A. 在最近一个季度末持有 Rigel Pharmaceuticals 0.11% 的股份，价值 548,000 美元。</p>
</div><p>Several other institutional investors also recently added to or reduced their stakes in the stock. Armistice Capital LLC grew its position in shares of Rigel Pharmaceuticals by 5.5% during the 2nd quarter. Armistice Capital LLC now owns 1,600,000 shares of the biotechnology company's stock valued at $29,968,000 after acquiring an additional 84,000 shares during the period. Dynamic Technology Lab Private Ltd bought a new stake in shares of Rigel Pharmaceuticals in the 1st quarter worth approximately $488,000. Strs Ohio purchased a new position in Rigel Pharmaceuticals in the first quarter valued at approximately $389,000. Acadian Asset Management LLC lifted its stake in Rigel Pharmaceuticals by 50.1% in the first quarter. Acadian Asset Management LLC now owns 565,045 shares of the biotechnology company's stock valued at $10,161,000 after purchasing an additional 188,679 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. grew its holdings in Rigel Pharmaceuticals by 7.8% during the first quarter. Jacobs Levy Equity Management Inc. now owns 217,776 shares of the biotechnology company's stock valued at $3,918,000 after purchasing an additional 15,687 shares during the period. Institutional investors own 66.23% of the company's stock.</p>
<div class="lb-trans"><p>其他几家机构投资者最近也增持或减持了该股票的持股。Armistice Capital LLC 在第二季度将其在 Rigel Pharmaceuticals 的持股比例增加了 5.5%。Armistice Capital LLC 目前持有该生物技术公司 1,600,000 股股票，价值 29,968,000 美元，此前在该期间内又增购了 84,000 股。Dynamic Technology Lab Private Ltd 在第一季度购买了 Rigel Pharmaceuticals 的新股份，价值约 488,000 美元。Strs Ohio 在第一季度购买了 Rigel Pharmaceuticals 的新股份，价值约 389,000 美元。Acadian Asset Management LLC 在第一季度将其在 Rigel Pharmaceuticals 的持股比例提高了 50.1%。Acadian Asset Management LLC 目前持有该生物技术公司 565,045 股股票，价值 10,161,000 美元，此前在上个季度又购买了 188,679 股。最后，Jacobs Levy Equity Management Inc. 在第一季度将其在 Rigel Pharmaceuticals 的持股比例增加了 7.8%。Jacobs Levy Equity Management Inc. 目前持有该生物技术公司 217,776 股股票，价值 3,918,000 美元，此前在该期间内又购买了 15,687 股。机构投资者持有该公司 66.23% 的股份。</p>
</div><p>Get <strong>Rigel Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Rigel Pharmaceuticals</strong> 的提醒：</p>
</div><h2>Rigel Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Rigel Pharmaceuticals 价格表现</h2>
</div><p>Shares of NASDAQ:RIGL opened at $44.66 on Friday. The company has a 50 day moving average of $39.93 and a 200 day moving average of $32.11. The company has a current ratio of 2.28, a quick ratio of 2.14 and a debt-to-equity ratio of 0.25. The stock has a market cap of $810.58 million, a P/E ratio of 7.24 and a beta of 1.11. Rigel Pharmaceuticals, Inc. has a 12 month low of $15.50 and a 12 month high of $52.24.</p>
<div class="lb-trans"><p>NASDAQ:RIGL 的股票周五开盘价为 44.66 美元。该公司的 50 日移动平均线为 39.93 美元，200 日移动平均线为 32.11 美元。该公司的流动比率为 2.28，速动比率为 2.14，债务与股本比率为 0.25。该股票的市值为 8.1058 亿美元，市盈率为 7.24，贝塔值为 1.11。Rigel Pharmaceuticals, Inc. 的 12 个月低点为 15.50 美元，12 个月高点为 52.24 美元。</p>
</div><p>Rigel Pharmaceuticals (NASDAQ:RIGL - Get Free Report) last announced its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $1.46 EPS for the quarter, beating the consensus estimate of $0.93 by $0.53. The firm had revenue of $69.46 million during the quarter, compared to the consensus estimate of $61.88 million. Rigel Pharmaceuticals had a net margin of 40.17% and a return on equity of 204.70%. As a group, sell-side analysts forecast that Rigel Pharmaceuticals, Inc. will post 0.22 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Rigel Pharmaceuticals (NASDAQ:RIGL - 获取免费报告) 最近于 11 月 4 日（星期二）公布了季度财报。这家生物技术公司报告季度每股收益为 1.46 美元，超出市场共识预期的 0.93 美元，超出幅度为 0.53 美元。该公司在季度内的收入为 6946 万美元，而市场共识预期为 6188 万美元。Rigel Pharmaceuticals 的净利润率为 40.17%，股本回报率为 204.70%。整体来看，卖方分析师预测 Rigel Pharmaceuticals, Inc. 本财年将发布 0.22 美元的每股收益。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>Several analysts have issued reports on the company. Weiss Ratings restated a &#34;hold (c+)&#34; rating on shares of Rigel Pharmaceuticals in a research note on Wednesday, October 8th. Wall Street Zen raised Rigel Pharmaceuticals from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Sunday, December 21st. Zacks Research cut Rigel Pharmaceuticals from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Friday, December 5th. Jefferies Financial Group upgraded shares of Rigel Pharmaceuticals from a &#34;hold&#34; rating to a &#34;buy&#34; rating and increased their target price for the stock from $23.00 to $42.00 in a research report on Wednesday, November 5th. Finally, Cantor Fitzgerald lifted their target price on shares of Rigel Pharmaceuticals from $32.00 to $38.00 and gave the stock a &#34;neutral&#34; rating in a research note on Wednesday, November 5th. Three research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of &#34;Hold&#34; and an average target price of $43.20.</p>
<div class="lb-trans"><p>几位分析师对该公司发布了报告。Weiss Ratings 在 10 月 8 日（星期三）的研究报告中重申了对 Rigel Pharmaceuticals 股票的 &#34;持有 (c+)&#34; 评级。华尔街 Zen 在 12 月 21 日（星期日）的报告中将 Rigel Pharmaceuticals 的评级从 &#34;持有&#34; 上调至 &#34;买入&#34;。Zacks Research 在 12 月 5 日（星期五）的研究报告中将 Rigel Pharmaceuticals 的评级从 &#34;强力买入&#34; 下调至 &#34;持有&#34;。Jefferies Financial Group 在 11 月 5 日（星期三）的研究报告中将 Rigel Pharmaceuticals 的评级从 &#34;持有&#34; 上调至 &#34;买入&#34;，并将该股票的目标价从 23.00 美元提高至 42.00 美元。最后，Cantor Fitzgerald 在 11 月 5 日（星期三）的研究报告中将 Rigel Pharmaceuticals 的目标价从 32.00 美元提高至 38.00 美元，并给予该股票 &#34;中性&#34; 评级。三位研究分析师对该股票给予了买入评级，四位分析师对该公司的股票给予了持有评级。根据 MarketBeat 的数据，该公司的共识评级为 &#34;持有&#34;，平均目标价为 43.20 美元。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on Rigel Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Rigel Pharmaceuticals 的最新股票分析</strong></p>
</div><h2>Rigel Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Rigel Pharmaceuticals 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>Rigel Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. Founded in 2003, Rigel focuses on the discovery, development and commercialization of novel small molecule therapeutics targeting immune, hematologic and oncologic diseases. Leveraging a proprietary chemistry platform and expertise in signal transduction pathways, the company aims to address significant unmet medical needs in both rare and common disorders.</p>
<div class="lb-trans"><p>Rigel Pharmaceuticals, Inc. 是一家临床阶段的生物制药公司，总部位于加利福尼亚州南旧金山。公司成立于 2003 年，专注于发现、开发和商业化针对免疫、血液和肿瘤疾病的新型小分子治疗药物。利用专有的化学平台和信号转导通路的专业知识，该公司旨在解决稀有和常见疾病中显著未满足的医疗需求。</p>
</div><p>Rigel's lead product, fostamatinib (commercially known as Tavalisse®), is an oral spleen tyrosine kinase (SYK) inhibitor approved in the United States for the treatment of adult patients with chronic immune thrombocytopenia (ITP).</p>
<div class="lb-trans"><p>Rigel 的主要产品 fostamatinib（商业名称为 Tavalisse®）是一种口服脾酪氨酸激酶 (SYK) 抑制剂，已在美国获得批准，用于治疗慢性免疫性血小板减少症 (ITP) 的成年患者。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Rigel Pharmaceuticals</li>
<li>Put $1,000 into this stock by Jan 1 [Not NVDA]</li>
<li>Turn your &#34;dead money&#34; into $306+ monthly (starting this month)</li>
<li>Washington prepares for war</li>
<li>Strange Crystal Metal Outperforms Silicon Up to 100X</li>
<li>33,000% boom from weird new “AI Fuel?”</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Rigel Pharmaceuticals</li>
<li>在 1 月 1 日之前将 1,000 美元投入这只股票 [不是 NVDA]</li>
<li>将你的 &#34;死钱&#34; 转变为每月 306 美元以上（从这个月开始）</li>
<li>华盛顿为战争做准备</li>
<li>奇怪的晶体金属性能超过硅达 100 倍</li>
<li>来自奇怪的新 “AI 燃料” 的 33,000% 繁荣？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UklHTA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=RIGL"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Rigel Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Rigel Pharmaceuticals 吗？</h2>
</div><p>Before you consider Rigel Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Rigel Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rigel Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄地向客户推荐的股票，以便在更广泛的市场注意到之前购买... 而 Rigel Pharmaceuticals 并不在名单上。</p>
</div><p>While Rigel Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Rigel Pharmaceuticals 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看五只股票</p>
</div>

Assenagon Asset Management S.A. 减少了其在 Rigel 制药公司（Rigel Pharmaceuticals, Inc. $RIGL）的持股